RxDoctor Payments Data

Mia Maiolatesi, PA

Physician Assistant · Moosic, PANPI 1639957822

Payments from drug & device makers

$6,489in general payments, 2019–2025

Across 391 payments — averaging $16.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$876
  • Teva Pharmaceuticals USA, Inc.$842
  • Johnson & Johnson$833
  • AbbVie$547
  • Neurocrine Biosciences, Inc.$497
  • Alkermes, Inc.$486
  • plus $2K from 15 others

What the payments were for

  • Food & beverage$6,40999%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,489 in reported general payments places this provider in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

See all physician assistant providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,566
Medicare patients
12
Services billed
27

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Clonazepam67$504
Alprazolam60$463
Desvenlafaxine Succinate ErDesvenlafaxine Succinate17$433
Duloxetine Hcl13$345
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine15$302
Lorazepam24$297
Fluoxetine Hcl20$284
Aripiprazole27$276
Lithium Carbonate19$242
Gabapentin12$196
Sertraline Hcl19$179
Topiramate12$163
Hydroxyzine Hcl15$143
Lamotrigine21$136
Escitalopram Oxalate11$116

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$89$17919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,643 physician assistant providers in Pennsylvania.

Other physician assistant in Moosic

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →